Shotlee LogoShotlee
🌿 Mucosal Healing🛡️ IBD Focus✅ Updated 2026

Best Peptide for Gut Inflammation

KPV, BPC-157, Larazotide & LL-37 — Ranked by Inflammation Mechanism (2026)

Gut inflammation peptides target distinct inflammatory pathways: KPV directly inhibits NF-kB (the master inflammatory transcription factor) in gut mucosa; BPC-157 reduces mucosal inflammation via VEGF and NO pathways while simultaneously driving repair; Larazotide prevents inflammatory triggers from entering the bloodstream by restoring tight junction integrity; LL-37 addresses dysbiosis-driven inflammation. None are FDA-approved for IBD, but all have strong mechanistic rationale. Track your gut inflammation protocol in Shotlee.

Download on theApp Store
Get it onGoogle Play

Top Gut Inflammation Peptides — Ranked by Mechanism

PeptideInflammatory Mechanism TargetedBest IndicationDeliveryEvidence Level
KPVNF-kB inhibition in gut epithelial cells and macrophages — master inflammatory pathwayIBD, Crohn's, ulcerative colitis active flaresOral or SC injection⭐⭐⭐⭐
BPC-157VEGF/NO/EGR-1 — mucosal repair + anti-inflammatory via gut protection compoundBroad gut inflammation, NSAID damage, leaky gutOral (arginine salt) or SC injection⭐⭐⭐⭐
Larazotide AcetateZonulin antagonist — blocks inflammatory trigger entry via tight junctionsCeliac disease, leaky gut-driven systemic inflammationOral capsule⭐⭐⭐⭐
LL-37Cathelicidin — gut antimicrobial, TLR modulation, dysbiosis-driven inflammationSIBO, gut dysbiosis, antimicrobial-driven inflammationOral or SC injection (caution)⭐⭐
Thymosin Alpha-1T-cell modulation, Th1/Th2 balance, gut immune dysregulationAutoimmune gut conditions, immune-mediated IBDSC injection⭐⭐⭐

KPV and BPC-157 have the most direct gut-specific anti-inflammatory data in IBD animal models. None are FDA-approved for IBD. [1, 2, 3]

Top Gut Inflammation Picks Explained

KPV — NF-kB Inhibition in Gut Mucosa

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH specifically responsible for its anti-inflammatory activity. Directly inhibits NF-kB signalling in gut epithelial cells and macrophages — the central inflammatory pathway upregulated in Crohn's disease and ulcerative colitis. Reduces IL-1beta, IL-6, and TNF-alpha in mucosal tissue without systemic immunosuppression. Used orally for localised mucosal delivery. The most targeted gut-specific anti-inflammatory peptide available, complementing BPC-157's broader repair mechanism.

BPC-157 — Mucosal Repair + Anti-Inflammation

The most comprehensively studied gut peptide. Addresses gut inflammation via multiple parallel pathways: VEGF-driven angiogenesis restores vascular supply to inflamed tissue; NO pathway activation improves mucosal blood flow and antimicrobial defences; EGR-1 upregulation drives collagen synthesis and epithelial repair. Unlike pure anti-inflammatory agents, BPC-157 simultaneously heals the structural damage caused by inflammation. Best used orally (arginine salt) for IBD and mucosal inflammation, SC injection for systemic effects.

Larazotide — Stop Inflammatory Triggers at the Gate

Larazotide Acetate addresses gut inflammation at its source: intestinal permeability. By blocking zonulin and restoring tight junctions, it prevents bacterial endotoxins (LPS), undigested food antigens, and microbial metabolites from crossing into the bloodstream — stopping the continuous systemic inflammatory trigger that drives autoimmunity and systemic inflammation in leaky gut. Phase 2/3 trial data for celiac disease demonstrates significant reduction in both permeability and inflammatory marker levels.

Thymosin Alpha-1 — Immune Balance

Approved in 35+ countries for immune conditions. In IBD, gut inflammation is driven partly by Th2-mediated autoimmune dysfunction. Thymosin Alpha-1 restores Th1/Th2 immune balance, reduces autoimmune gut inflammation, and supports normal intestinal immune homeostasis. Best used as an adjunct in autoimmune IBD cases where immune dysregulation — not just local inflammation — is the primary driver. SC injection 1.6 mg 2x weekly.

LL-37 — Dysbiosis-Driven Inflammation

Gut dysbiosis and SIBO create sustained local inflammation by producing endotoxins (LPS) that activate TLR4 receptors in the intestinal wall. LL-37 addresses this by directly killing pathological gram-negative bacteria, modulating TLR signalling to prevent excessive inflammatory activation, and supporting the restoration of healthy gut microbiome composition. Use with caution — LL-37's effects on commensal bacteria are complex, and dose and delivery method require careful consideration.

How to Choose the Right Gut Inflammation Peptide

For active IBD flares (Crohn's or ulcerative colitis), the strongest protocol combines KPV (NF-kB inhibition, direct mucosal anti-inflammation) with BPC-157 oral arginine salt (structural repair and mucosal protection). This addresses both the inflammatory pathway driving tissue damage and the physical mucosal injury that results. For maintenance between flares, BPC-157 alone provides ongoing mucosal protection.

If intestinal permeability is a significant component — as evidenced by elevated zonulin, positive LPS antibodies, or multiple food sensitivities — add Larazotide to close the tight junction gap that allows inflammatory triggers to continuously enter circulation. For autoimmune IBD with systemic immune dysregulation, Thymosin Alpha-1 addresses the adaptive immune component that purely gut-targeted peptides cannot.

These peptides should be used as complements to conventional IBD management, not replacements for prescribed medications. Discuss any peptide protocol with your gastroenterologist. Track gut symptom scores, inflammatory biomarkers (faecal calprotectin, CRP), and daily quality-of-life measures in Shotlee to build objective evidence of protocol efficacy.

Track Your Gut Inflammation Protocol in Shotlee

Log every dose, daily gut symptom rating, and inflammatory biomarker result in Shotlee. Build the objective data your gastroenterologist can review and that shows whether your peptide protocol is reducing mucosal inflammation.

How to Track Your Gut Inflammation Protocol in Shotlee

01

Baseline: record current gut symptom scores (pain, bloating, stool frequency/consistency, blood in stool if relevant) and any available inflammatory markers (faecal calprotectin, CRP, ESR)

02

Log each peptide dose with compound, form (oral vs injectable), dose, and time — for KPV and BPC-157 oral, record whether taken fasted or with food

03

Rate daily gut symptom severity using a consistent 0–10 scale at the same time each evening

04

Schedule a faecal calprotectin test at 6–8 weeks to compare to baseline — this is the most sensitive non-invasive IBD activity marker

05

Track flare frequency over the protocol — note dates of any flare episodes and how they compare to pre-protocol flare history

Frequently Asked Questions

KPV is the most targeted gut anti-inflammatory peptide — it directly inhibits NF-kB in gut mucosal cells and macrophages, the central pathway in IBD inflammation. BPC-157 is broader, addressing both repair and inflammation simultaneously. For active IBD flares, combining KPV + BPC-157 oral provides both anti-inflammatory and regenerative effects on the gut mucosa.

Animal models of Crohn's disease (TNBS-induced colitis) consistently show BPC-157 reduces mucosal damage scores, decreases inflammatory cytokines (IL-6, TNF-alpha), and accelerates healing of colonic lesions. Human clinical trials for Crohn's disease are in early stages, but physician-reported case series describe significant symptom improvement with oral BPC-157 arginine salt protocols. It is not FDA-approved for Crohn's disease.

KPV and BPC-157 target different aspects of gut inflammation and are complementary. KPV is more specifically anti-inflammatory — better for active mucosal inflammation. BPC-157 is more broadly healing — better for structural damage, motility issues, and vascular repair alongside inflammation. For IBD flares, combining both is the most evidence-aligned protocol.

When tight junctions between intestinal epithelial cells are disrupted (increased intestinal permeability), bacterial endotoxins (LPS), food antigens, and microbial metabolites enter the bloodstream. These trigger systemic immune activation — producing low-grade chronic inflammation that drives autoimmunity, metabolic dysfunction, and mood disorders. Larazotide specifically targets this pathway by restoring tight junction integrity and blocking the inflammatory trigger at source.

KPV, BPC-157, and Larazotide have not been studied in formal drug interaction trials with biologic IBD medications (infliximab, adalimumab, vedolizumab) or immunomodulators (azathioprine, methotrexate). Use only under physician supervision. Do not reduce or stop prescribed IBD medications without gastroenterological oversight.

References

  1. [1]ReviewDalmasso G, et al. "The Peptide KPV Inhibits the Cytokine-Induced Pro-inflammatory Response in Intestinal Epithelial Cells." J Cell Biochem. 2008;103(6):1927-1940.
  2. [2]ReviewSikiric P, et al. "BPC-157 as a Therapy for Inflammatory Bowel Disease." Curr Pharm Des. 2011;17(16):1612-1632.
  3. [3]Clinical TrialKelly CP, et al. "Larazotide acetate in patients with coeliac disease undergoing a gluten challenge." Aliment Pharmacol Ther. 2013;37(2):252-262.

Track Your Gut Inflammation Protocol in Shotlee

Log every dose, daily symptom score, and faecal calprotectin result. Build the objective evidence that your gut inflammation protocol is working.

🚀 Use Shotlee for Free